Background and aims Coronavirus disease 2019 (COVID-19) imposes a substantial and
ongoing burden on the US healthcare system and society. Molnupiravir is a new oral …

By January 2022 over ten billion doses of COVID-19 vaccines had been administered
worldwide. Concerns about COVID-19 vaccine-associated thrombosis arose after the …

OBJECTIVES We assessed BNT162b2 vaccine effectiveness (VE) against mild to moderate
and severe coronavirus disease 2019 (COVID-19) in children and adolescents through the …

1. Background The Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2)
epidemic began in late December 2019 in the Hubei province of Wuhan, China, and the …

COVID-19 has affected the lives and well-being of billions of citizens worldwide. While
nondrug interventions have been partially effective in containing the COVID-19 epidemic …

Introduction A rapid increase in COVID-19 cases due to the spread of the Delta and Omicron
variants in vaccinated populations has raised concerns about the hospitalization risk …

There is uncertainty about the seroprevalence of anti-SARS-CoV-2 antibodies in the general
population of Austria and about the waning of antibodies over time. We conducted a …

Since its emergence in late 2019, the coronavirus disease 2019 (COVID‐19) pandemic has
caused substantial morbidity and mortality. Despite the availability of efficacious vaccines …

Background The decrease in physical function resulting from COVID-19 infection exerts a
substantial negative influence on the quality of life of individuals. Physical activity plays a …

Background This study aimed to analyze coronavirus disease 2019 (COVID-19) vaccine
policies and effectiveness in Korea, Japan, and Singapore, thereby providing empirical …